Brineura hit with NICE rejection
NICE is rejecting NHS funding for a £500,000-a-year drug to treat Batten disease on concerns over its long-term effectiveness.
Read More
Tag: neuronal ceroid lipofuscinosis type II
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
